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doi:10.1016/j.jmii.2011.04.007Recently, forkhead/winged-helix family box protein P3 (FOXP-3) was described as the main
regulator of regulatory T cells’ activity. This transcription factor has the ability to control
the immunosuppressive response of regulatory T cells. FOXP-3 has binding sites for different
genes specific for proteins with various important functions. In this article, selected FOXP-3-
dependent genes with known functions were divided into two groups. The first group of genes
has main immunoregulatory functions, and the second group has the ability to regulate
apoptosis and tumorigenesis. Investigation of the functions of all FOXP-3-dependent genes
opens perspectives for applications in different fields of basic and clinical research.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Regulatory T cells (Tregs) are a subpopulation of CD4þ cells
and primarily maintain the immune system homeostasis of
the organism. These cells have a high immunosuppressive
potential for both innate and adaptive immunities. Distur-
bance of the cellular homeostasis results in either self-
reactive autoimmune aggression or immune deficiency.
The investigation of T cells with suppressive activity beganof Pediatrics and Center for
icine, Charles University, Ke
public.
ail.com.
an Society of Microbiology. Publin 1970, when new subpopulation of T-lymphocytes with
immunosuppressive properties was first described.1 Since
this initial observation, numerous articles characterizing
T cells with immune regulatory properties have been pub-
lished; however, the mechanisms inherent to the immune
response in these cells have not been fully elucidated.
Forkhead/winged-helix family box protein P3 and
immunodysregulation, polyendocrinopathy,
enteropathy, X-linked syndrome
The immune response that characterizes Tregs is realized
through the action of the forkhead/winged-helix family box
protein P3 (FOXP-3) (Scurfin). The functional activity ofished by Elsevier Taiwan LLC. All rights reserved.
FOXP-3-dependent genes in immune regulation, tumorigenesis and apoptosis 413CD4þCD25þ Tregs depends on the high expression of FOXP-3
gene and protein. FOXP-3 is a homodimer consisting of
a proline-rich domain at the N-terminus in addition to
a C2H2 zinc finger and a leucine zipper located in the center
of the amino acid sequence. This central domain partici-
pates primarily in proteineprotein interactions, whereas the
C-terminal end of FOXP-3 is a forkhead DNA-binding domain.
FOXP-3 has regions that allow it to bind to approximately
700 genes and intergenically encoded microRNAs. In addi-
tion, FOXP-3 may have opposing effects on different genes,
facilitating the transcription of some genes while repressing
the transcription of others. Changes or defects in the coding
sequence of the FOXP3 gene result in the development of
different pathological conditions. Complete inactivation of
FOXP3 gene because of a condition known as immuno-
dysregulation, polyendocrinopathy, enteropathy, X-linked
(IPEX) syndrome. IPEX syndrome is very rare in humans and
has only been observed in male patients. This syndrome is
characterized by a number of complications, including
diarrhea, a failure to thrive, eczema, atopic psoriasiform
dermatitis, alopecia, hemolytic anemia, thrombocytopenia,
neutropenia, hypo- or hyperthyroidism, lymphoadenopathy,
Type 1 diabetes mellitus, and increased susceptibility to
infections. Other clinical complications may include respi-
ratory distress, bruising, hypocalcemia, hepatic paren-
chymal disease, cholestasis, hypertension, cardiomegaly,
glomerulopathy, encephalopathy, and testicular atrophy.
IPEX animal models show a phenotype characteristic of the
scurfy mouse.2 These animals have scaly skin, progressive
anemia, thrombocytopenia, leucocytosis, lymphoadenop-
athy, various infections, diarrhea, gastrointestinal injury,
cachexia, and hypogonadism in males, and they typically die
within the first few weeks after birth. FOXP-3-related acti-
vation of Tregs has been demonstrated by the hypersensi-
tivity of scurfy mice to activation through the T cell
receptors.3 Different changes of the regulation control by
the FOXP-3 of FOXP-3-dependent genes result in alteration
of Tregs functions and also because of further specific
autoimmune disorders, such as systemic lupus eryth-
ematosus, rheumatoid arthritis, ulcerative colitis, Crohn’s
disease, celiac disease, hemolytic anemia, and asthma.4 All
genetic abnormalities that result in the onset of the IPEX
syndrome and other selective syndromes as a consequence
of mutations in genes dependent on FOXP-3 can be
explained mainly by unspecific autoimmune aggression that
is attributed to some aspects of the regulation of T cells and
also the misbalance of regulation of FOXP-3-dependent
genes, which is the result of separate manifestations of
IPEX syndrome. In recent reports by Sugimoto et al. (2006),5
Zheng et al. (2007),6 and Hill et al. (2007),7 these authors
were the first who indicated the presence of FOXP-3-related
genes in natural and induced Tregs by detecting differences
in marker genes in CD4þCD25 and CD4þCD25þ cells.5e7
In this article, 10 genes were selected from all FOXP-3-
dependent genes detected in the investigations of Sugimoto
et al. (2006),5 Zheng et al. (2007),6 and Hill et al. (2007)7 in
connection with any of the following criteria: high degree of
down- or upregulation of separate gene expression after
functional activation of Tregs and high FOXP3 gene expres-
sion; proof of synchronous expression of FOXP3 gene and
protein and selected gene expression by other authors; and
the importance of genes in regulations of immune reactionsand CD4þCD25þ cells functions. The genes described were
divided into two groups: one of them is a group of genes
capable of changing the immune response and the other
group includes genes that may regulate apoptosis and
tumorigenesis. The influence [induction (þ) or inhibition
()] of high expression of FOXP-3 on every described gene
expression is indicated in Table 1.
Immune response regulation
The main function of FOXP-3 is to influence Tregs activity
and, as a result, there is a possibility to regulate the activity
of the immune reactions. The group of FOXP-3-dependent
genes that are known to code separate proteins that may
change the immune response was indicated. FOXP-3 may
change expression of these genes because of suppression or
activation of immune response members. The most well-
known genes from the aforementioned group include the
cytotoxic T-lymphocyte-associated 4 (CTLA-4); inducible
costimulator (ICOS); cyclic Adenosine Monophosphate-
responsive element modulator (CREM); and PR [positive
regulatory domain Iebinding factor 1 (PRDI-BNF1)-RIZ]
domain containing 1, zinc finger (PRDM1) genes.5e7
Cytotoxic T-lymphocyte-associated 4
The CTLA-4 protein is coded by CTLA-4 gene, and it is
similar to the lymphocyte CD28 molecule structure, with
the exception that it is more competitive than CD28. CTLA-
4 has a higher binding affinity to CD80 (B7.1) and CD86
(B7.2) in antigen-presenting cells.8 Furthermore, inhibition
of monocytes and macrophages by CTLA-4 is one of the
primary mechanisms to repress the immune response by
Tregs.9 The up-expression of this receptor protein is also
regulated by the FOXP-3 protein in natural and induced
Tregs.10 Interestingly, the application of the CTLA-4 anti-
body or specific deficiency of CTLA-4 caused the expected
effects of severe yet reversible T cell-mediated autoim-
mune disease.11 The low level of CTLA-4 expression was
observed in patients with juvenile idiopathic arthritis.12
Some human studies had shown that the administration of
antibody to CTLA-4 resulted in tumor necrosis.8
Inducible costimulator
Another marker of FOXP-3 activity is ICOS.13 The ICOS gene
codes a protein ICOS, which participates in T cell receptor
stimulation of T cells. In this case, CD28 is not required for
the induction of ICOS. Data have indicated that there is an
association between the expression of ICOS and the
production of some cytokines. High expression of ICOS was
correlated with the production of interleukin (IL)-10 in
Tregs.14 Two subpopulations of CD4þCD25þ natural Tregs
were detected. One subset expressed ICOS and another
ICOS-negative subpopulation of Tregs. The ICOSþ Tregs
produced IL-10 and transforming growth factor (TGF)-b to
suppress T cells and dendritic cells. The ICOSˉ Tregs
produced TGF-b only to suppress T cells. Development of
Type 1 diabetes mellitus and common variable immunode-
ficiency was associated with disturbances of ICOS expres-
sion in Tregs.15
Table 1 The pluseminus effect of FOXP-3 on some gene expressions in CD4þCD25þ regulatory T cells
Gene Synonyms Influence of FOXP-3
on gene expressiona
References
CTLA-4 CD, CD152, CD28, CELIAC3, CTLA-4, GSE, IDDM12,
insulin-dependent diabetes mellitus 12
þ Sugimoto N et al. (2006)5; Zheng Y et al. (2007)6; Zheng SG et al.
(2006)10; Hill JA et al. (2007)7; Holmberg D et al. (2005)11
ICOS Activation-inducible lymphocyte immunomediatory
molecule, AILIM, CD278, inducible T cell
costimulator, MGC39850
þ Sugimoto N et al. (2006)5; Zheng Y et al. (2007)6; Hill JA et al.
(2007)7; Strauss L et al. (2008)13; Honkanen J et al. (2008)15
ICER/CREM cAMP-responsive element modulator, hCREM-2,
ICER, inducible cAMP early repressor, MGC111110,
MGC17881, MGC41893
þ Sugimoto N et al. (2006)5; Zheng Y et al. (2007)6; Hill JA et al.
(2007)7; Bodor J et al. (2007)16; Bodor J et al. (2007)19
PRDM1 Beta-interferon gene positive regulatory
domain Iebinding factor, BLIMP1, BLIMP-1,
MGC118922, MGC118923, MGC118924, MGC118925,
positive regulatory domain Iebinding factor 1,
PRDI-BF1, PRDI-binding factor 1, PR domain-containing
protein 1, PR domain zinc finger protein 1
þ Sugimoto N et al. (2006)5; Zheng Y et al. (2007)6; Hill JA et al.
(2007)7; Seddiki N (2009)21
GITR Activation-inducible TNFR family receptor, AITR, GITR,
GITR-D, glucocorticoid-induced TNFR-related protein,
tumor necrosis factor receptor superfamily member 18,
UNQ319/PRO364
þ Sugimoto N et al. (2006)5; Zheng Y, et al. (2007)6; Hill JA, et al.
(2007)7; de Boer OJ et al. (2007)26
PD-1 CD279, hPD-1, hPD-l, PD1, programmed cell death
protein 1, protein PD-1, SLEB2
þ Sugimoto N et al. (2006)5; Zheng Y et al. (2007)6; Hill JA et al.
(2007)7; Wang L et al. (2008)28
IL-7Ra CD127, CDw127, CDW127, IL7RA, IL-7R-alpha, ILRA,
interleukin-7 receptor subunit alpha
 Sugimoto N et al. (2006)5; Zheng Y et al. (2007)6; Hill JA et al.
(2007)7; Liu W et al. (2006)32; Shen LS et al. (2009)33
NRP1 BDCA4, CD304, DKFZp686A03134, DKFZp781F1414,
neuropilin-1, NP1, NRP, vascular endothelial cell
growth factor 165 receptor, VEGF165R
þ Sugimoto N et al. (2006)5; Zheng Y et al. (2007)6; Hill JA et al.
(2007)7; Bielenberg DR et al. (2006)34; Hansen W et al. (2006)35
TGFBR1 and TGFBR2 AAT5, activin receptor-like kinase 5, ACVRLK4,
ALK5, ALK-5, LDS1A, LDS2A, serine/threonine-protein
kinase receptor R4, SKR4, TbetaR-I, TGF-beta receptor
type 1, TGF-beta receptor type I, TGF-beta Type I
receptor, TGFR-1, transforming growth factor-beta
receptor Type I
þ Sugimoto N et al. (2006)5; Zheng Y et al. (2007)6; Hill JA et al.
(2007)7; Li X et al. (2007)37
ECM1 Extracellular matrix protein 1, secretory
component p85
þ Sugimoto N et al. (2006)5; Zheng Y et al. (2007)6; Hill JA et al.
(2007)7; Miyara and Sakaguchi (2007)39; Wang L et al. (2003)40
a “þ” Indicates upregulation of gene expression and “” indicates downregulation of gene expression.
cAMPZ cyclic Adenosine Monophosphate; CREMZ cAMP-responsive element modulator; CTLA-4Z cytotoxic T-lymphocyte-associated 4; ECM1Z extracellular matrix protein 1; FOXP-
3Z forkhead/winged-helix family box protein P3; GITRZ glucocorticoid-induced TNFR related; ICERZ inducible cAMP early repressor; ICOSZ inducible costimulator; IL-7RaZ inter-
leukin-7Ra; NRP-1Z neuropilin-1; PRDI-BF1Z positive regulatory domain Iebinding factor 1; PRDM1Z positive regulatory domain Iebinding factor 1-RIZ domain containing 1, zinc finger;
TGFBR1Z transforming growth factor receptor 1; TGFBR2Z transforming growth factor receptor 2.
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element modulator
CREM is upregulated in Tregs, located in natural and
induced Tregs, and is dependent on FOXP-3 expression.16
CREM protein activity is dependent on the concentration
of intracellular calcium, which in turn regulates the activity
of calcineurin and nuclear factor of activated T-cells
(NFAT). Ca2þ signaling leads to the activation of the members
of the NFAT in the absence of AP-1. NFAT/activator protein
(AP)-1 is a transcriptional complex, which upregulates the
expression of genes involved in immune response. In the
absence of AP-1, NFAT promotes T cell anergy program.
Anergized T cells express increased levels of IL-10.17 CREM
modulates immune response, which was observed in the
regulation of antimicrobial defense and immunity.18 CREM
also regulates cyclooxygenase-2, which suppresses effector
FOXP3 T cells by a prostaglandin E2-dependent mecha-
nism.19 The role of CREM in the pathogenesis of diseases
was observed in systemic lupus erythematosus and heart
failure.20PR (PRDI-BF1-RIZ) domain containing 1, zinc finger
PRDM1 is another protein-coding FOXP3-related gene that is
expressed in Tregs.21 PRDM1 was originally identified as
PRDI-BF1, which functions as an inducible repressor of the
transcription of the b-interferon gene expression.22 This
gene is essentially needed for terminal differentiation of
B-lymphocytes to antibody-producing plasma cells. It highly
expressed in effector and memory T cells of both CD4 and
CD8 subpopulations. PR domain zinc finger protein 1 (Beta-
interferon gene positive regulatory domain I-binding factor)
deficiency in T cells is because of enhanced proliferation
and lethal multiorgan inflammatory disorders.22 Blimp-1
may directly and indirectly repress interleukin 2 gene by
means of FBJ murine osteosarcoma viral oncogene
homolog, which is one of the components of AP-1 and is
a strong activator of interleukin 2 gene. In the absence of
Blimp-1, IL-2 levels might greatly increase, which causes
autoaggressive response.23Regulation of apoptosis and tumorigenesis
The other primary function of FOXP-3 is the regulation of
genes coding apoptotic proteins. FOXP-3 expression induces
apoptotic surface factors and suppresses intracellular and
nucleic factors, including glucocorticoid-induced tumor
necrosis factor receptor (TNFR)-related (GITR) protein,
programmed cell death (PD)-1, and IL-7Ra.5e7 The FOXP-3
protein may regulate genes that are involved in tumori-
genesis.24 Tumor cells release tumor growth factor beta in
addition to some other factors that activate the prolifera-
tion of Tregs. Antibody-mediated FOXP-3 protein therapy
induced apoptosis in cancer cells and inhibited metastasis,
which was observed in breast, ovarian, and colon cancer
cells.25 FOXP-3 may be expressed by tumor cells. FOXP-3
also controls genes known to facilitate both the oncogenic
transformation of cells and the processes of metastatic
progression, such as neuropilin-1 (NRP-1), transforminggrowth factor beta receptor (TGFBR) 1, TGFBR2, and
extracellular matrix protein 1 (ECM1).
Glucocorticoid-induced TNFR-related protein
GITR protein, a receptor belonging to the TNFR super-
family, is activated by GITR ligand (GITRL). GITRL belongs
to the tumor necrosis factor family and is a Type II trans-
membrane protein. GITRL is expressed on antigen-
presenting cells and B cells but not in T cells. GITR is
expressed at low levels in resting responder T cells and is
highly expressed in Tregs, and it is recognized as a marker
of Tregs.26 GITR protein stimulates T cellemediated anti-
tumor immunity in mice. In humans, high expression of
GITR in primary gastrointestinal cancers and tumor cell
lines of different histological origin was observed.27
PD-1
The PD-1 belongs to CD28 family of receptors, expressed on
T cells, B cells, and myeloid cells. These receptors are
transmembrane proteins and are expressed as monomers.
PD-1 binds to PD-L1 (B7-H1) and PD-L2 (B7-DC), which are
homologs of B7-1 and B7-2 and are induced on antigen-
presenting cells, and on various nonimmune cells. PD-1
negatively regulates cell activation and proliferation,
causing cell cycle arrest without apoptosis. PD-1 recruits
the protein tyrosine phosphatase, non-receptor type 11.
PD-1 inhibits chronically activated cells and responses in
peripheral, nonlymphoid tissues. PD-1 is expressed in Tregs,
which promote the regulation of immune responses by these
cells.28 PD-1 may have intra- and extracellular localization.
Activation of Tregs with high expression of FOXP-3 results
in extracellular expression of PD-1.29 Mice with knockout
PD-1 gene develop autoimmune cardiomyopathy or a lupus-
like syndrome. In humans, part of the immune deficiency
associated with HIV infection may also be because of
PD-1-mediated inhibition of T cell activation.30
Interleukin-7Ra
The IL-7Ra (CD127) is a Type I cytokine receptor chain
devoid of intrinsic tyrosine kinase activity. It can bind IL-7
because of janus kinase 3-mediated phosphorylation of
IL-7Ra and recruitment of janus kinase 2 and signal trans-
ducer and activator of transcription 5 transcription factors.
IL-7 stimulates survival and expansion of immature
precursors committed to the T and B cells. Patients with
IL-7Ra deficiency present with signs and symptoms of
severe combined immune deficiency, characterized by
failure to thrive, recurrent otitis, viral infections, candidi-
asis, diarrhea, and fever.31 Although most CD4þ human T
cells express IL-7Ra, Tregs exhibiting suppressive activity
in vitro display distinctly lower surface expression of this
marker. Expression of CD127 negatively correlates with
FOXP-3 content, because FOXP-3 interacts with the CD127
promoter, contributing to the low expression of CD127 in
CD4þCD25þ Tregs.32 Recent publications also propose that
high expression of CD127 can modulate Tregs functions and
decrease its suppressive activity. This fact was observed in
patients with gastric cancer.33
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NRP1 codes NRP-1 protein. NRP-1 is a surface marker of
CD4þCD25þ Tregs. NRPs are membranous receptors capable
of binding two disparate ligands, Class 3 semaphorins, and
vascular growth factor, and regulating two diverse systems,
neuronal guidance, and angiogenesis. NRP-1 is predomi-
nantly expressed on carcinomas.34 The expression of NRP-1
by tumor cells is of great interest because NRP-1 and TGF-
b1 have been linked to cancer progression. NRP-1 is an
important factor that binds to TGF-b1 in its activated and
latency-associated peptide forms. NRP-1 is a receptor for
TGF-b1 in Tregs, and it promotes Tregs activity.35 In recent
publications, it was proposed to use NRP-1 blockers for
treatment of cancers.36
TGFBR1 and TGFBR2
Another FOXP3-related gene is TGFBR1. This gene codes
protein TGF-bR1, which interacts with TGF-bR2 for further
formation of complex with TGF-b1. Biochemically, TGF-bR1
and TGF-bR2 are serine/threonine kinases, which phosphor-
ylate Smads. Furthermore to Smads, TGF-b1 also activates
other signaling pathways, including various mitogen-
activated protein kinases and phosphatidylinositol-3 kinase.
TGF-b1 downregulates the proliferation and effector func-
tions of T cells and the activation of macrophages. TGF-b
and TGF-bR1 regulates differentiation or survival of Tregs.
TGF-b signaling induces expression of the FOXP-3 and
generation of Tregs from activated CD4þ T cells.37 TGF-b
signaling is frequently perturbed in many human cancers,
including renal cell carcinomas, colorectal cancer, non-
small-cell lung cancer, and transitional cell carcinoma.38
Extracellular matrix protein 1
The ECM1 gene codes similarly named extracellular matrix
protein. This is a secreted protein that has been implicated
with extracellular matrix formation, cell adhesion, cell
signaling, and regulation of tissue differentiation and
maturation. Mutation of the ECM1 gene, leading to
autosomal-recessive genodermatosis, lipoid proteinosis,
also known as UrbacheWiethe disease, which is charac-
terized by generalized thickening of the skin and mucosal
infiltration with scarring. ECM-1 interacts with other
extracellular matrix components, such as polysaccharides
(hyaluronan, heparin, chondroitin sulfate A) and proteins
[fibronectin, collagen IV, matrix metallopeptidase (MMP-
9)], either as its reservoir or as its cofactor. The ECM-1
protein supports the processes of angiogenesis. It stimu-
lates the proliferation of endothelial cells and promotes
blood vessel formation, which may be the result of tumor
progression and metastasis formation. Expression of ECM-1
closely correlates with the expression of FOXP-3 in
CD4þCD25þ Tregs.39 High expression of ECM-1 factor indi-
cates the poor prognosis and metastatic progression of
invasive breast ductal carcinoma, esophageal squamous
carcinoma, gastric cancer, and colorectal cancer.40
The primary function of FOXP-3-dependent genes is
regulation of the immune responses by means of changes of
CD4þCD25þ Tregs functionality, which may lead todisorders of the metabolism of various substances, disrup-
tions in hormonal regulation, and misbalance in the cell
cycle, and others. In this review, the main (immune
response, apoptosis, and tumorigenesis regulation) func-
tions of 10 FOXP-3-dependent genes are described,
although many of FOXP-3-dependent genes and their
functions remain unknown. Understanding the biological
properties of FOXP-3 would have a wide range of implica-
tions for salvation of problems of immune escape in
cancers, treatment of autoimmune disorders, regulation of
inflammation, and immune response to infectious diseases.
It is possible that the development of new strategies with
genetic manipulations with the aim to change the expres-
sion of FOXP3 or FOXP-3-dependent genes may be helpful in
the elaboration of new principles for treatment of many
diseases and theirs complications.References
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